Long Term Outcome of a Third Anti-TNF Monoclonal Antibody in IBD After the Failure of Two Other Anti-TNF Agents- Data From a North American Study

被引：0
|
作者：
de Silva, Punyanganie S.
Nguyen, Deanna D.
Yajnik, Vijay
Korzenik, Joshua R.
Ananthakrishnan, Ashwin N.
机构：
来源：
GASTROENTEROLOGY | 2012年 / 142卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S63 / S64
页数：2
相关论文
共 50 条
  • [1] Efficacy of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF
    Mozziconacci, Nicolas
    Vermeire, Severine
    Laharie, David
    Louis, Edouard
    Bigard, Marc-Andre
    Hebuterne, Xavier
    Bouhnik, Yotam
    Van Assche, Gert A.
    Lemann, Marc
    Rutgeerts, Paul J.
    Colombel, Jean-Frederic
    Allez, Matthieu
    [J]. GASTROENTEROLOGY, 2008, 134 (04) : A663 - A663
  • [2] The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies
    Allez, M.
    Vermeire, S.
    Mozziconacci, N.
    Michetti, P.
    Laharie, D.
    Louis, E.
    Bigard, M. -A.
    Hebuterne, X.
    Treton, X.
    Kohn, A.
    Marteau, P.
    Cortot, A.
    Nichita, C.
    van Assche, G.
    Rutgeerts, P.
    Lemann, M.
    Colombel, J. -F.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 31 (01) : 92 - 101
  • [3] Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease
    de Silva, P. S. A.
    Nguyen, D. D.
    Sauk, J.
    Korzenik, J.
    Yajnik, V.
    Ananthakrishnan, A. N.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 36 (05) : 459 - 466
  • [4] What is the best strategy after failure to anti-TNF? Ustekinumab or other anti-TNF?
    Cerpa Arencibia, A.
    Suarez Ferrer, C.
    Poza Cordon, J.
    Martin Arranz, E.
    Ramirez, L.
    Martin Arranz, M. D.
    [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S554 - S554
  • [5] Outcome in ulcerative colitis after switch from subcutaneous anti-TNF to intravenous anti-TNF: A multicentre study
    Viola, A.
    Pugliese, D.
    Renna, S.
    Furfaro, F.
    Caprioli, F.
    D'Inca', R.
    Bossa, F.
    Costantino, G.
    Fantini, M.
    Fiorino, G.
    Armuzzi, A.
    Orlando, A.
    Fries, W.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S418 - S418
  • [6] OUTCOME IN ULCERATIVE COLITIS AFTER SWITCH FROM SUBCUTANEOUS ANTI-TNF TO INTRAVENOUS ANTI-TNF: A MULTICENTRE STUDY
    Viola, A.
    Pugliese, D.
    Renna, S.
    Furfaro, F.
    Caprioli, F.
    D'Inca, R.
    Bossa, F.
    Costantino, G.
    Fantini, M. C.
    Fiorino, G.
    Armuzzi, A.
    Orlando, A.
    Fries, W.
    [J]. DIGESTIVE AND LIVER DISEASE, 2018, 50 (02) : E193 - E193
  • [7] LONG-TERM OUTCOME OF ANTI-TNF THERAPY
    Sieper, J.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (04) : 601 - 601
  • [8] Does failure to respond to one anti-TNF agent in Ulcerative Colitis predict treatment failure with other anti-TNF agents?
    AlAlawi, F.
    Keegan, D.
    Byrne, K.
    Mulcahy, H.
    Cullen, G.
    Doherty, G.
    [J]. JOURNAL OF CROHNS & COLITIS, 2015, 9 : S254 - S254
  • [9] Does Failure to Respond to One Anti-TNF Agent in Ulcerative Colitis Predict Treatment Failure With Other Anti-TNF Agents
    AlAlawi, Fatema
    Keegan, Denise
    Byrne, Kathryn
    Mulcahy, Hugh
    Cullen, Garret
    Doherty, Glen A.
    [J]. GASTROENTEROLOGY, 2015, 148 (04) : S266 - S267
  • [10] After failure of an anti-TNF it is unknown whether another anti-TNF or a new biological should be administered in second or third intention
    Du Pan, S. Martin
    Scherer, A.
    Gabay, C.
    Finckh, A.
    [J]. SWISS MEDICAL WEEKLY, 2011, 141 : S4 - S4
12345